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Abstract
Background: MicroRNAs (miRNAs) are a class of small noncoding RNAs that regulate gene expression. They are aberrantly
expressed in many types of cancers. In this study, we determined the genome-wide miRNA profiles in bladder urothelial
carcinoma by deep sequencing.
Methodology/Principal Findings: We detected 656 differentially expressed known human miRNAs and miRNA antisense
sequences (miRNA*s) in nine bladder urothelial carcinoma patients by deep sequencing. Many miRNAs and miRNA*s were
significantly upregulated or downregulated in bladder urothelial carcinoma compared to matched histologically normal
urothelium. hsa-miR-96 was the most significantly upregulated miRNA and hsa-miR-490-5p was the most significantly
downregulated one. Upregulated miRNAs were more common than downregulated ones. The hsa-miR-183, hsa-miR-
200b,429, hsa-miR-200c,141 and hsa-miR-17,92 clusters were significantly upregulated. The hsa-miR-143,145 cluster was
significantly downregulated. hsa-miR-182, hsa-miR-183, hsa-miR-200a, hsa-miR-143 and hsa-miR-195 were evaluated by Real-
Time qPCR in a total of fifty-one bladder urothelial carcinoma patients. They were aberrantly expressed in bladder urothelial
carcinoma compared to matched histologically normal urothelium (p,0.001 for each miRNA).
Conclusions/Significance: To date, this is the first study to determine genome-wide miRNA expression patterns in human
bladder urothelial carcinoma by deep sequencing. We found that a collection of miRNAs were aberrantly expressed in
bladder urothelial carcinoma compared to matched histologically normal urothelium, suggesting that they might play roles
as oncogenes or tumor suppressors in the development and/or progression of this cancer. Our data provide novel insights
into cancer biology.
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Introduction
Bladder cancer is one of the most prevalent malignancies in the
world. About 357,000 bladder cancer cases were newly diagnosed
and 145,000 cancer-related deaths were estimated in 2002 [1].
Urothelial carcinoma of the bladder, the most common histo-
pathologic type of bladder cancer, has a variety of genetic and
phenotypic characteristics. Many factors, such as chromosomal
anomalies, genetic polymorphisms, genetic and epigenetic alter-
ations, contribute to tumorigenesis and progression of urothelial
carcinoma of the bladder [2].
MicroRNAs (miRNAs) are endogenous, noncoding RNA
molecules of about 22 nucleotides in length that regulate gene
expression [3]. They join the RNA-induced silencing complex to
regulate their targeted messenger RNA (mRNA) by repressing
mRNA translation and/or directing mRNA cleavage [4]. miRNAs
play important roles in normal development, cell growth,
differentiation, and apoptosis in mammals [5].
More than half miRNA genes are located in cancer-associated
genomic regions or in fragile sites [6]. Aberrantly expressed miRNAs
have been shown to be associated with many types of cancers. Both
losses and gains of miRNA function contribute to cancer develop-
ment. miRNAs act as oncogenes or tumor suppressors [7]. Most
importantly, different cancer types, stages or differentiation states
haveunique miRNAexpression profiles, suggestingthat miRNAs can
function as novel biomarkers for cancer diagnosis [8,9].
Several previous researches used miRNA microarrays with
limited and varied probes to profile the miRNA expression in
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e18286bladder cancer and their results did not always indicate consistent
results [10–13]. To better understand the role of miRNAs in
bladder cancer development and progression, comprehensive
analysis of the expression and abundance of miRNAs in this
cancer is required. With the merit of the high-throughput deep
sequencing technology, genome-wide cancer miRNAs can be
quantitatively and accurately determined. Here, we present the
genome-wide miRNA profiles in nine pairs of snap-frozen bladder
urothelial carcinoma and matched histologically normal urothe-
lium by deep sequencing. We found that a collection of miRNAs
were aberrantly expressed in bladder urothelial carcinoma
compared to matched histologically normal urothelium, several
of which were evaluated by Real-Time qPCR in a total of fifty-one
bladder urothelial carcinoma patients.
Results
Overview of miRNA profiles
Known miRNA expression files between bladder urothelial
carcinoma and matched histologically normal urothelium from
each patient were compared to find out the differentially expressed
miRNAs. The expression of miRNAs in paired samples were
shown by calculating log2Ratio. The procedures are shown as
below: (1) Normalize the expression of miRNAs in two samples
(tumor versus normal) to get the expression of transcript per
million (TPM). Normalized expression=Actual miRNA count/
Total count of clean reads*1000000. (2) Calculate fold-change and
p value from the normalized expression. Then Calculate log2-
Ratio. Fold-change=log2Ratio (tumor/normal). We determined
656 differentially expressed known human miRNAs and miRNA
antisense sequences (miRNA*s) in miRBase14.0 in nine bladder
urothelial carcinoma patients (Table S1).
We identified a great number of miRNAs and miRNA*s that
were signicantly upregulated or downregulated in these patients
and could discriminate bladder urothelial carcinoma from
matched normal urothelium. hsa-miR-96 (log2Ratio=4.664328)
was the most significantly upregulated miRNA and hsa-miR-490-5p
(log2Ratio=25.79794) was the most significantly downregulated
one (Table 1). Selected differentially expressed miRNAs were
validated by Real-Time qPCR. The Real-Time qPCR findings
correlated well with the sequencing analysis. The comparison
between Real-Time qPCR findings and deep sequencing results is
shown in Figure 1. The counts of upregulated and downregulated
miRNAs varied in different patients. Upregulated miRNAs were
more common than downregulated ones (Figure 2). Additionally,
we identified a remarkable divergence of expression levels between
miRNA and paired miRNA*. The expression levels of miRNAs
were usually higher than that of paired miRNA*s (Figure 3).
Besides the known miRNAs and miRNA*s, 92 novel miRNA
sequence candidates were detected in our study (Table S2). Most
of them were expressed at very low levels and only in certain
samples. Their expression patterns and possible roles need further
investigation.
Expression of clustered miRNAs
We found that a collection of deregulated miRNA clusters were
expressed. The hsa-miR-183, hsa-miR-200b,429, hsa-miR-
200c,141 and hsa-miR-17,92 clusters were significantly
upregulated. The hsa-miR-143,145 cluster was significantly
downregulated.
Real-Time qPCR validation
hsa-miR-182, hsa-miR-183, hsa-miR-200a, hsa-miR-143 and hsa-
miR-195 were evaluated by Real-Time qPCR in a total of fifty-one
bladder urothelial carcinoma patients. hsa-miR-182, hsa-miR-183
and hsa-miR-200a were overexpressed hsa-miR-143 and hsa-miR-
195 were underexpressed in bladder urothelial carcinoma
compared to matched histologically normal urothelium
(p,0.001 for each miRNA) (Table S3).
Table 1. A collection of deregulated miRNAs detected by
deep sequencing in nine bladder carcinoma patients.
Upregulated in cancer Downregulated in cancer
miRNA log2Ratio
a miRNA log2Ratio
b
hsa-miR-96 4.664327577 hsa-miR-490-5p 25.79794
hsa-miR-182 4.095720336 hsa-miR-99a* 25.11761
hsa-miR-183 3.820320401 hsa-miR-490-3p 24.93958
hsa-miR-429 3.071280539 hsa-miR-125b-2* 24.68986
hsa-miR-141 3.040138264 hsa-miR-99a 24.00745
hsa-miR-200c 2.780906641 hsa-miR-133a 24.20124
hsa-miR-200a 2.77846432 hsa-miR-1 23.97239
hsa-miR-200b 2.747966283 hsa-miR-125b 23.32189
hsa-miR-18a 2.527819159 hsa-miR-145 23.15196
hsa-miR-7 2.553138 hsa-miR-195 22.11536
hsa-miR-25* 2.398581 hsa-miR-143* 22.93729
hsa-miR-19b 2.075886368 hsa-miR-145* 22.78189
hsa-miR-19a 2.05391435 hsa-let-7c 22.51985
hsa-miR-17 1.732520894 hsa-miR-100 22.37375
hsa-miR-20a 1.644486659 hsa-miR-143 22.53496
a,bBladder urothelial carcinoma versus matched histologically normal
urothelium, False discovery rate (FDR)#0.1%, p,0.01.
doi:10.1371/journal.pone.0018286.t001
Figure 1. The comparison between deep sequencing data and
Real-Time qPCR results. For the comparison between deep
sequencing data and Real-Time qPCR results, hsa-miR-182, hsa-miR-
183, hsa-miR-200a, hsa-miR-143 and hsa-miR-195 determined to be
differentially expressed in bladder urothelial carcinoma compared to
matched histologically normal urothelium in nine patients by deep
sequencing were validated using Real-Time qPCR. The heights of the
columns in the chart represent the log-transformed median fold
changes (tumor/normal) in expression across the nine patients for each
of the five miRNAs validated; the bars represent standard errors. The
validation results of the five miRNAs indicated that the deep
sequencing data correlated well with the Real-Time qPCR results.
doi:10.1371/journal.pone.0018286.g001
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The development of high throughput deep sequencing technol-
ogy provides the possibility of a near complete view of miRNA
profiles. Deep sequencing technology has the potential to identify
novel tissue specific miRNAs [14]. It determines the absolute
abundance of miRNAs and can discover novel miRNAs that have
been missed by common cloning and sequencing methods [15].
Deep sequencing technology is superior to microarrays which
determine limited known miRNAs and usually do not contain the
full list of known miRNA antisense sequences. Up to now deep
sequencing technology has been the gold standard for the
comprehensive analysis of miRNAs.
Researches have revealed that miRNAs can be used as
biomarkers for different types of cancers [8,9]. Some miRNAs as
biomarkers are able to trace the tissue of origin of cancers of
unknown primary origin [16]. Specific miRNA signatures are
superior to mRNA signatures in predicting the prognosis of lung
cancer [17].
In this work, we used deep sequencing technology to determine
the comprehensive miRNA expression profiles in nine pairs of
snap-frozen bladder urothelial carcinoma and matched histolog-
ically normal urothelium. Many miRNAs were significantly
upregulated or downregulated in bladder urothelial carcinoma
compared to matched histologically normal urothelium in these
patients, suggesting that these aberrantly expressed miRNAs might
play roles in these cancers. The most significantly upregulated
miRNA hsa-miR-96 has been reported to be oncogenic [18], but
the role of the most significantly downregulated miRNA hsa-miR-
490-5p is not clear. A lot of miRNA*s were significantly
deregulated in bladder urothelial carcinoma compared to matched
histologically normal urothelium in this study. Some miRNA*s can
join the RNA-induced silencing complex and have inhibitory
function [19].
Many deregulated miRNA clusters were expressed according to
our deep sequencing analysis. We found that the hsa-miR-183
cluster was overexpressed in bladder cancer. This cluster consists
of hsa-miR-96, hsa-miR-182 and hsa-miR-183 and is located on
chromosome 7. These three miRNAs are upregulated in prostate
carcinoma [18]. The coexpression pattern of the miRNAs of this
cluster in cancers suggests they might play roles together. The hsa-
miR-200 family of miRNAs (hsa-miR-200a/b/c, hsa-miR-141 and
hsa-miR-429) were overexpressed in bladder cancer. The hsa-miR-
200b,429 cluster is located on chromosome 1 and the hsa-miR-
200c,141 cluster is located on chromosome 12. The coexpression
of these clusters suggests that they might be controlled by common
factors and play roles together. hsa-miR-200b, hsa-miR-200a and
hsa-miR-429 miRNAs are encoded by a single polycistronic
transcript and negatively regulated by ZEB1 and SIP1 [20].
TGFß 1 can downregulate the hsa-miR-200 family leading to the
upregulation of ZEB1 and ZEB2 [21]. The hsa-miR-200 family are
also overexpressed in ovarian and cervical cancers [22–24],
suggesting this miRNA family are oncogenic in seveval cancers.
The hsa-miR-17-92 cluster is located on chromosome 13 and acts
as oncogenes. E2F1 and E2F3 can directly activate the
transcription of these miRNAs [25]. The hsa-miR-143,145 cluster
is located on chromosome 5 and downregulated in many cancers,
including bladder cancers and their cell lines [13,26]. Our findings
provided more evidence to support that the hsa-miR-143,145
cluster is tumor-suppressive in bladder cancer.
In this study, Real-Time qPCR was performed to evaluate the
expression patterns of hsa-miR-182, hsa-miR-183, hsa-miR-200a,
hsa-miR-143 and hsa-miR-195 in a total of fifty-one bladder
urothelial carcinoma patients. hsa-miR-182, hsa-miR-183 and hsa-
miR-200a were overexpressed hsa-miR-143 and hsa-miR-195 were
underexpressed in bladder urothelial carcinoma compared to
matched histologically normal urothelium. These findings sup-
ported our deep sequencing analysis.
We compared our results to published data to seacrch for
independent external validations. hsa-miR-182, hsa-miR-183 and
hsa-miR-224 are upregulated and hsa-miR-1, hsa-miR-101, hsa-miR-
143, hsa-miR-145, hsa-miR-127 and hsa-miR-29c are downregulated
in bladder urothelial carcinoma compared to matched histolog-
ically normal urothelium [27]. Our deep sequencing results were
largely consistent with these findings. The upregulation of hsa-miR-
182 and hsa-miR-183 and the downregulation of hsa-miR-143 were
found in bladder urothelial carcinoma compared to matched
Figure 3. The expression of miRNA and paired miRNA*. A
collection of miRNAs and paired miRNA antisense sequences (miRNA*s)
were determined to be expressed in nine bladder urothelial carcinoma
patients by deep sequencing. We identified a remarkable divergence of
expression between miRNA and paired miRNA*. The expression of
miRNA/miRNA* pairs is shown in scatter plot with logarithm coordinate
system; each point represents the expression of a miRNA/miRNA* pair.
In most miRNA/miRNA* pairs, the expression level of miRNA was higher
than that of paired miRNA*. In a small number of miRNA/miRNA* pairs,
miRNA was less abundant than paired miRNA*.
doi:10.1371/journal.pone.0018286.g003
Figure 2. The counts of upregulated and downregulated
miRNAs. Many miRNAs were determined to be significantly upregu-
lated or downregulated in bladder urothelial carcinoma compared to
matched histologically normal urothelium in nine patients by deep
sequencing. The counts of upregulated and downregulated miRNAs
varied across the nine patients. In eight out of nine bladder urothelial
carcinoma patients upregulated miRNAs were more common than
downregulated ones. In only one patient (Patient No. B13), upregulated
miRNAs were less common than downregulated ones.
doi:10.1371/journal.pone.0018286.g002
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evaluation. The profiling of miRNAs in 106 bladder cancers and
11 normal samples using microarrays has revealed that a set of
miRNAs are upregulated or downregulated in bladder cancers
[13]. Of these deregulated miRNAs, hsa-miR-21, hsa-miR-20a, hsa-
miR-184, hsa-miR-26a, hsa-miR-125b, hsa-miR-29a, hsa-miR-29c and
so on share the similar expression patterns with our results. hsa-
miR-133a, hsa-miR-133b and hsa-miR-195 are downregulated in
bladder cancers [28]. These miRNAs showed downregulation in
our sequencing analysis and hsa-miR-195 downregulation was
comfirmed by Real-Time qPCR in this study.
We used matched adjacent histologically normal urothelium as
control in our study. It has been reported that select samples of
histologically normal urothelium from bladder cancer patients
have genetic alterations [29]. Some chromosomal aberrations
shared by both a tumor and a histologically normal looking tissue
adjacent to the tumor can cause similar changes of miRNA
expression. To compensate for this weakness, we compared our
results to several published reports using urothelium from normals
as control [10,13,28]. A large collection of findings were
comparable between theirs and ours. Our findings were also
consistent with those papers using matched adjacent histologically
normal urothelium as control concerning a lot of miRNAs [26,27].
Overlapping findings between published data and our results are
shown in Table 2.
To the best of our knowledge, this is the first genome-wide
profiling of miRNAs in human bladder cancer by deep
sequencing. We found that a collection of deregulated miRNAs
were aberrantly expressed in bladder urothelial carcinoma
compared to matched histologically normal urothelium, suggesting
that they might play roles as oncogenes or tumor suppressors in
the development and/or progression of this cancer. Our data
provide novel insights into cancer biology. More work will be
needed to determine the potential roles of miRNAs as diagnostic
biomarkers and candidate therapeutic targets for bladder cancer.
Materials and Methods
Patient samples
Written informed consent was obtained from all patients and
the study was approved by the Institutional Review Board of
Peking University Shenzhen Hospital. Fifty-one patients with
bladder urothelial carcinoma who received partial or radical
cystectomy were included in the study. Of these patients, nine
were used for initial deep sequencing analysis of miRNAs and
forty-two were used for an extra evaluation. Bladder urothelial
carcinoma was diagnosed histopathologically. Bladder urothelial
carcinoma and matched histologically normal urothelium from
each subject were snap-frozen in liquid nitrogen immmediately
after resection. Detailed information of nine bladder urothelial
carcinoma patients in deep sequencing set is summarized in
Table S4.
RNA Extraction
When the proportion of cancer cells in a tissue section was
greater than 80%, the frozen block was subjected to RNA
extraction. Total RNA was extracted from fifty-one pairs of snap-
frozen bladder urothelial carcinoma and matched histologically
normal urothelium using TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s protocol. The RNA
integrity was evaluated by Agilent 2100 BioAnalyzer (Agilent
Technologies, Palo Alto, CA, USA).
miRNA sequencing and analysis
Eighteen small RNA libraries prepared from nine pairs of snap-
frozen bladder urothelial carcinoma and matched histologically
normal urothelium were constructed, amplified and sequenced.
Total RNA was used for miRNA sequencing. After 59adapter and
39adapter were ligated to small RNAs, Reverse transcription was
performed. Then PCR was performed and PCR products were
purified. Lastly, miRNA libraries were constructed and sequenced
by the Illumina Cluster Station and Genome Analyze (Illumina
Inc, CA, USA) at Beijing Genomics Institute at Shenzhen
according to the manufacturer’s protocol.
Low quality reads were removed and adapter sequences were
accurately clipped with the aid of a dynamic programming
algorithm before further analysis. After elimination of duplicate
reads, the remaining reads of at least 18 nt were mapped to a
human reference genome (hg19) using SOAP V2.0 [30]. To
identify sequence tags originating from coding exons, repeats,
rRNA, tRNA, snRNA, and snoRNA, UCSC RefGene, Repeat-
Table 2. Overlapping findings between published data and current results.
Control miRNA upregulated in cancer miRNA downregulated in cancer Reference
Urothelium from normals hsa-miR-193a-3p, hsa-miR-21, hsa-miR-143, hsa-miR-145, [13]
hsa-miR-20a, hsa-miR-184, hsa-miR-126*,hsa-miR-26a,
hsa-miR-492 hsa-miR-125b, hsa-miR-29a
Urothelium from normals hsa-miR-223, hsa-miR-26b, [10]
hsa-miR-185, hsa-miR-203,
hsa-miR-23a, hsa-miR-205
Urothelium from normals hsa-miR-133a, hsa-miR-133b, [28]
hsa-miR-195, hsa-miR-145,
hsa-miR-125b
Matched urothelium
a hsa-miR-182, hsa-miR-183, hsa-miR-1, hsa-miR-101, [27]
hsa-miR-224, hsa-miR-196a, hsa-miR-143, hsa-miR-145,
hsa-miR-10a, hsa-miR-203 hsa-miR-127, hsa-miR-29c
Matched urothelium
b hsa-miR-143 [26]
a,bMatched histologically normal urothelium from bladder urothelial carcinoma patients.
doi:10.1371/journal.pone.0018286.t002
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from the NCBI Genbank data (http://www.ncbi.nih.gov) were
used. To identify novel miRNA genes, all hairpin-like RNA
structures encompassing small RNA tags were identified using
MIREAP (http://sourceforge.net/projects/mireap).
Real-Time qPCR confirmation and statistical methods
Three overexpressed (hsa-miR-182, hsa-miR-183 and hsa-miR-
200a) and two underexpressed miRNAs (hsa-miR-143 and hsa-miR-
195) were evaluated in all of the patients included in this study.
These miRNAs were selected because they were significantly
deregulated in the initial deep sequecing analysis. snRNA U6 was
used as the endogenous control. Real-Time qPCR was performed
using the All-in-One
TM miRNA qRT-PCR Detection Kit
(GeneCopoiea Inc, Rockville, MD, USA). 10 mg of total RNA
was converted to cDNA according to the manufacturer’s protocol.
PCR was performed in a total reaction volume of 20 ml, including
10 ml of 2xAll-in-One
TM qPCR Mix, 2 ml of Universal Adaptor
PCR Primer (2 mM), 2 ml of All-in-One
TM qPCR Primer (2 mM),
2 ml of First-Strand cDNA (diluted in 1:5), 50xROX Reference
Dye 0.4 ml and 3.6 ml double-distilled water. The reactions were
performed and analyzed using the ABI PRISM 7000 Fluorescent
Quantitative PCR System (Applied Biosystems, Foster City,
CA,USA). PCR reactions were performed for cancer and normal
cDNA in triplicate for each set. The cycling parameters for PCR
were as follows: (1) an initial denaturation step of 15 min at 95uC;
(2) 40 cycles, with 1 cycle consisting of 15 s at 95uC, 20 s at 55uC,
and 30 s at 70uC. The catalog numbers of All-in-One
TM miRNA
qPCR Primers are listed in Table S5. The median in each
triplicate was used to calculate relative miRNA concentrations
(DCt=CtmedianmiRNA2CtmediansnRNAU6). Expression fold changes
were calculated using 2
2DDCt methods [31]. The miRNA
expression differences between cancer and control were analysed
using Student’s t test within SPSS (Version 16.0 SPSS Inc.). A
value of p,0.05 was considered as statistically significant.
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